title: Inhibition of indoleamine 2,3-dioxygenase not only blocks autoreactive B cell activation, but it also reduces production of antibodies in general: comment on the article by Pigott and Mandik-Nayak.
authors.forename: Theodoros
authors.initials: T
authors.lastname: Eleftheriadis
authors.forename: Georgios
authors.initials: G
authors.lastname: Pissas
authors.forename: Vassilios
authors.initials: V
authors.lastname: Liakopoulos
authors.forename: Ioannis
authors.initials: I
authors.lastname: Stefanidis
mesh_terms: D000818:Animals; D001169:Arthritis, Experimental / Q000628:therapy*; D001323:Autoantibodies / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology*; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000037:antagonists & inhibitors*; D008212:Lymphocyte Depletion / Q000379:methods*; D014364:Tryptophan / Q000031:analogs & derivatives*
chemical_list: D001323:Autoantibodies; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D014364:Tryptophan